Stock VTVT VTV THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases vTv Therapeutics Inc.

Equities

VTVT

US9183852048

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
17.1 USD -2.84% Intraday chart for vTv Therapeutics Inc. -26.70% +48.70%
May. 09 VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 VTv Therapeutics Inc. Announces Board Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
PR
VTv Therapeutics: Q1 Earnings Snapshot
AQ
VTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
AQ
VTv Therapeutics : 2024 Notice of Annual Meeting and Proxy Statement
PU
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
PR
VTv Therapeutics: Q4 Earnings Snapshot
AQ
VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
AQ
VTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
AQ
VTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
AQ
VTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
AQ
VTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
AQ
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
PR
VTv Therapeutics: Q3 Earnings Snapshot
AQ
VTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
AQ
VTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
AQ
VTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
AQ
VTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
AQ
CANTEX AND ALLEGHENY HEALTH NETWORK ANNOUNCE INITIATION OF A PHASE 1/2 STUDY OF AZELIRAGON IN PATIENTS REFRACTORY TO FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER
AQ
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
PR
CANTEX PHARMACEUTICALS ANNOUNCES INITIATION OF AN INVESTIGATOR-INITIATED PHASE 2 CLINICAL TRIAL INVESTIGATING AZELIRAGON COMBINED WITH STEREOTACTIC RADIOSURGERY FOR THE TREATMENT OF BRAIN METASTASES
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VTVT Stock
  4. News vTv Therapeutics Inc.
  5. Press Releases